Xcelerate (OTCMKTS:XCRT – Get Rating) and Sema4 (NASDAQ:SMFR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Profitability
This table compares Xcelerate and Sema4’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xcelerate | N/A | N/A | N/A |
| Sema4 | -121.31% | -53.31% | -36.04% |
Earnings & Valuation
This table compares Xcelerate and Sema4’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xcelerate | N/A | N/A | N/A | N/A | N/A |
| Sema4 | $231.15 million | 0.51 | -$245.39 million | ($0.93) | -0.33 |
Risk & Volatility
Xcelerate has a beta of 3.32, indicating that its stock price is 232% more volatile than the S&P 500. Comparatively, Sema4 has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Xcelerate and Sema4, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xcelerate | 0 | 0 | 0 | 0 | N/A |
| Sema4 | 0 | 2 | 3 | 0 | 2.60 |
Sema4 has a consensus target price of $2.67, indicating a potential upside of 758.55%. Given Sema4’s higher probable upside, analysts plainly believe Sema4 is more favorable than Xcelerate.
Insider & Institutional Ownership
56.0% of Sema4 shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
About Xcelerate
Xcelerate, Inc. engages in dental equipment, which develops, manufactures and markets atmospheric water generators for the dental market, home and office use. It provides dental networks for union members. The company was founded on November 26, 1996 and is headquartered in Mauldin, SC.
About Sema4
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for Xcelerate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xcelerate and related companies with MarketBeat.com's FREE daily email newsletter.
